Evidence map›Paper›PMID 33777662›Full record

ArticleJournal of kidney cancer and VHL2021

Germline Pathogenic Variants Identified by Targeted Next-Generation Sequencing of Susceptibility Genes in Pheochromocytoma and Paraganglioma.

Sinem Yalcintepe, Hakan Gurkan, Fatma Nur Korkmaz, Selma Demir, Engin Atli, Damla Eker, Hazal Sezginer Guler, Drenusha Zhuri, Emine Ikbal Atli, Semra Ayturk Salt and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of kidney cancer and VHL, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Sinem YalcintepeDepartment of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Hakan GurkanDepartment of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Fatma Nur KorkmazDepartment of Endocrinology and Metabolism, Faculty of Medicine, Ankara University, Ankara, Turkey.
Selma DemirDepartment of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Engin AtliDepartment of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Damla EkerDepartment of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Hazal Sezginer GulerDepartment of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Drenusha ZhuriDepartment of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Emine Ikbal AtliDepartment of Medical Genetics, Faculty of Medicine, Trakya University, Edirne, Turkey.
Semra Ayturk SaltDivision of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey.
Mustafa SahinDepartment of Endocrinology and Metabolism, Faculty of Medicine, Ankara University, Ankara, Turkey.
Sibel GuldikenDivision of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey.
Trakya University · TRAnkara University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to evaluate germline variant frequencies of pheochromocytoma and paraganglioma targeted susceptibility genes with next-generation sequencing method. Germline DNA from 75 cases were evaluated with targeted next-generation sequencing on an Illumina NextSeq550 instrument.

Indexed as

paragangliomapheochromocytomasusceptibility genestargeted sequencing

Identifiers

PMID33777662
PMCPMC7969383
OpenAlexW3138056900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.